Orchid Pharma share price
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Formerly Orchid Chemicals & Pharmaceuticals
Last close ₹823.30down ₹52.25 (5.97%)BSE ₹826.10
Share price at the NSE close on 23 Oct 2026. Previous close ₹875.55.
52-week range of traded prices to 23 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,930 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 Aug 2026
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,70,48053.5% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹304 Crdown 17.42%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3.22 Crdown 87.52%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 1.1%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 5 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2021, the company reports a discontinued business. From the year to Mar 2026, the company's revenue for that year, ₹1,233 Cr, differs from its quarters added, ₹942 Cr.
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 13 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 11 Nov | Sep 2025Filed 11 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 14 Aug | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 173 | 194 | 207 | 368 | 304 |
| Net profit | 27 | 21 | 22 | 15 | −6 | −13 | 26 | 3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 12.2% | 9.6% | 9.4% | 8.7% | −3.0% | −6.1% | 7.0% | 1.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
The quarters either side of a change of basis do not compare. From the quarter to Mar 2026, the company's revenue for the year to Mar 2026, ₹1,233 Cr, differs from its quarters added, ₹942 Cr.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −37.8% | −91.6% | +635.8% | 0.0% |
| 3 years | +8.0% | −47.3% | +104.9% | 0.0% |
| 5 years | −27.5% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2026.
Mutual funds holding it
26 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 8 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- AddedAdded. Funds that held more shares than at the end of the month before.
- 4
- CutCut. Funds that held fewer shares than at the end of the month before.
- 4
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 18
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 quant Small Cap Fundquant Mutual Fund | 34,65,947 | 0.97% | ₹345.6 Cr |
 UTI Value FundUTI Mutual Fund | 11,88,926 | 1.31% | ₹118.5 Cr |
 Invesco India Contra FundInvesco Mutual Fund | 9,90,763 | 0.51% | ₹98.8 Cr |
 Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 9,42,962 | 0.62% | ₹94.0 Cr |
| UTI Small Cap FundUTI Mutual Fund | 5,09,966 | 0.97% | ₹50.8 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 4,87,811 | 2.53% | ₹48.6 Cr |
| Invesco India Small Cap FundInvesco Mutual Fund | 4,55,183 | 0.28% | ₹45.4 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 4,54,372 | 0.13% | ₹45.3 Cr |
| Kotak Consumption FundKotak Mahindra Mutual Fund | 2,86,000 | 1.72% | ₹28.5 Cr |
| Kotak Multi Cap FundKotak Mahindra Mutual Fund | 2,64,308 | 0.09% | ₹26.4 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Orchid Pharma in market cap.
Orchid Pharma is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Innova CaptabINNOVACAP | 5,650 | 36.1 | 5.2 | 23.1 | +34.5% | +20.4% | 15.3% | 15.0% | 0.20% |
 Senores PharmaceuticalsSENORES | 5,597 | 42.6 | 6.0 | 28.2 | – | – | 15.3% | 13.1% | 0.00% |
 Sun Pharma Advanced Research CompanySPARC | 5,574 | 3.5 | 4.2 | 3.8 | +2,855.8% | – | 118.4% | 84.8% | 0.00% |
 FDCFDC | 5,514 | 18.8 | 2.2 | 16.3 | +3.4% | +8.7% | 12.3% | 11.1% | 1.48% |
 IOL Chemicals and PharmaceuticalsIOLCP | 4,818 | 28.7 | 2.7 | 15.3 | +18.6% | +60.1% | 9.6% | 11.8% | 0.61% |
 Novartis IndiaNOVARTIND | 4,505 | 46.1 | 5.5 | 37.7 | +5.4% | −4.9% | 12.2% | 12.2% | 0.00% |
 RPG Life SciencesRPGLIFE | 4,333 | 36.3 | 7.2 | 27.0 | +11.8% | −34.6% | 21.0% | 21.3% | 0.92% |
 Zota Health CareZOTA | 4,304 | – | 6.2 | 1,419.0 | +78.9% | – | −22.5% | −12.8% | 0.08% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
20 Oct · Board meeting
15 Oct · Board meeting
Sep 2026
Orchid Pharma share price by year
Each calendar year to 2025.Orchid Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 758.95 | −58.0% | 1,982.50 | 628.75 |
| 2024 | 1,807.05 | +153.6% | 1,829.90 | 709.60 |
| 2023 | 712.50 | +95.7% | 734.70 | 334.20 |
| 2022 | 364.05 | −7.8% | 445.75 | 269.30 |
| 2021 | 394.90 | +220.4% | 2,527.90 | 129.40 |
| 2020 | 123.25 | – | 123.25 | 18.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 3 Nov 2020.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 879.95 | 880.25 | 809.05 | 823.30 | 824.40 | 1,70,480 | 53.5% |
| 22 Oct 2026 | 877.05 | 885.10 | 860.75 | 875.55 | 873.34 | 52,511 | 39.8% |
| 21 Oct 2026 | 885.10 | 911.90 | 872.50 | 886.90 | 892.59 | 1,08,837 | 40.5% |
| 19 Oct 2026 | 911.25 | 941.50 | 875.00 | 893.50 | 906.80 | 1,27,390 | 27.1% |
| 16 Oct 2026 | 935.00 | 938.95 | 896.00 | 911.25 | 908.64 | 1,04,768 | 50.3% |
| 15 Oct 2026 | 945.25 | 950.25 | 925.00 | 928.05 | 937.54 | 42,563 | 47.4% |
| 14 Oct 2026 | 959.95 | 968.30 | 940.00 | 945.25 | 954.89 | 35,546 | 46.1% |
| 13 Oct 2026 | 975.10 | 981.75 | 947.00 | 959.95 | 961.61 | 50,365 | 49.5% |
| 12 Oct 2026 | 989.00 | 998.75 | 970.55 | 979.35 | 982.88 | 24,791 | 42.1% |
| 9 Oct 2026 | 990.00 | 1,001.75 | 961.55 | 983.95 | 982.57 | 75,527 | 41.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Offer for sale history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 3 Nov 2020 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 17 Mar 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- Legal name
- Orchid Pharma Limited
- NSE symbol
- ORCHPHARMA
- BSE code
- 524372
- ISIN
- INE191A01027
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 1993 on BSE, Jul 2010 on NSE
- Face value
- ₹10
- Former symbols
- ORCHIDPHAR, ORCHIDCHEM, ORCHIDCHEM
- CIN
- L24222TN1992PLC022994
- Corporate identity number, the registrar of companies' code for it